ALK-Abello AS (ALK B) – Financial and Strategic SWOT Analysis Review

ALK-Abello AS (ALK B) – Financial and Strategic SWOT Analysis Review Cover

Single Licence: $125

Buy Now
customer(s) bought this report
BUY WITH CONFIDENCE

Shopping on CFDMaster.com is Safe and Secure. GUARANTEED!
All information is encrypted and handled by PayPal.com

Need Assistance?
Have you got questions about this report? Why not speak to one of our advisors. Email us at business@cfdmaster.com or call us at +61 (02) 8011 3208
# Pages
Market
Country
Single User
Site License
Enterprisewide
45
Pharmaceuticals and Healthcare
Denmark

ALK-Abello AS (ALK B) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

– Business description – A detailed description of the company’s operations and business divisions.
– Corporate strategy – Analyst’s summarization of the company’s business strategy.
– SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
– Company history – Progression of key events associated with the company.
– Major products and services – A list of major products, services and brands of the company.
– Key competitors – A list of key competitors to the company.
– Key employees – A list of the key executives of the company.
– Executive biographies – A brief summary of the executives’ employment history.
– Key operational heads – A list of personnel heading key departments/functions.
– Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
– Key manufacturing facilities – A list of key manufacturing facilities of the company.
– Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
– Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

ALK-Abello A/S (ALK) is a research-driven pharmaceutical company. It holds expertise in conducting allergy research and is the world leader in allergy immunotherapy. The company undertakes the discovery, development and commercialization of immune-therapeutics for allergy prevention, diagnosis and treatment. ALK’s product portfolio includes allergy immunotherapy products such as tablet-based allergy vaccines, sublingual (drop-based) allergy vaccines, and subcutaneous allergy vaccines; adrenaline auto-injector for emergency treatment; and other allergy diagnostics.

ALK-Abello AS Key Recent Developments

Nov 14, 2014 ALK-Abello Announces Nine-Month Interim Report (Q3) 2014
Aug 13, 2014 ALK-Abello announces six-month interim report (Q2) 2014
Jul 01, 2014 ALK appoints new Executive Vice President for Product Supply
May 08, 2014 ALK-Abello: Three-month interim report 2014

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
– The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
– The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
– Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
– Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
– Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Table of Contents

Section 1 – About the Company 6
ALK-Abello A/S – Key Facts 6
ALK-Abello A/S – Key Employees 7
ALK-Abello A/S – Key Employee Biographies 8
ALK-Abello A/S – Major Products and Services 9
ALK-Abello A/S – Pharmaceutical Pipeline Products Data 10
ALK-Abello A/S, Pipeline Products by Therapy Area 10
ALK-Abello A/S, Pipeline Products by Development Phase 11
ALK-Abello A/S – History 13
ALK-Abello A/S – Company Statement 16
ALK-Abello A/S – Locations And Subsidiaries 17
Head Office 17
Other Locations & Subsidiaries 17
ALK-Abello A/S – Key Manufacturing Facilities 19
Section 2 – Company Analysis 20
ALK-Abello A/S – Business Description 20
ALK-Abello A/S – Corporate Strategy 21
ALK-Abello A/S – SWOT Analysis 22
SWOT Analysis – Overview 22
ALK-Abello A/S – Strengths 22
Strength – Dominent Position in Europe 22
Strength – Focused R&D Activities 22
Strength – Increase in Revenue 22
ALK-Abello A/S – Weaknesses 23
Weakness – Decreased Revenue from Other products and Services 23
Weakness – Increasing Trade Receivables 23
ALK-Abello A/S – Opportunities 24
Opportunity – Market Potential: Asthma 24
Opportunity – bioCSL Partnership 24
Opportunity – Robust Product Pipeline 24
ALK-Abello A/S – Threats 25
Threat – Foreign Exchange Risk 25
Threat – Uncertain R&D Outcomes 25
Threat – Regulatory Environment 25
ALK-Abello A/S – Key Competitors 26
Section 3 – Company Financial Ratios 27
Financial Ratios – Capital Market Ratios 27
Financial Ratios – Annual Ratios 28
Performance Chart 30
Financial Performance 30
Financial Ratios – Interim Ratios 31
Financial Ratios – Ratio Charts 32
Section 4 – Company’s Lifesciences Financial Deals and Alliances 33
ALK-Abello A/S, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 33
ALK-Abello A/S, Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015 34
ALK-Abello A/S, Recent Deals Summary 35
Section 5 – Company’s Recent Developments 36
Nov 14, 2014: ALK-Abello Announces Nine-Month Interim Report (Q3) 2014 36
Aug 13, 2014: ALK-Abello announces six-month interim report (Q2) 2014 37
Jul 01, 2014: ALK appoints new Executive Vice President for Product Supply 38
May 08, 2014: ALK-Abello: Three-month interim report 2014 39
Feb 05, 2014: ALK releases its annual report 2013 40
Section 6 – Appendix 41
Methodology 41
Ratio Definitions 41
About GlobalData 45
Contact Us 45
Disclaimer 45



List of Tables
ALK-Abello A/S, Key Facts 6
ALK-Abello A/S, Key Employees 7
ALK-Abello A/S, Key Employee Biographies 8
ALK-Abello A/S, Major Products and Services 9
ALK-Abello A/S, Number of Pipeline Products by Therapy Area 10
ALK-Abello A/S, Number of Pipeline Products by Development Stage 11
ALK-Abello A/S, Pipeline Products By Therapy Area and Development Phase 12
ALK-Abello A/S, History 13
ALK-Abello A/S, Other Locations 17
ALK-Abello A/S, Subsidiaries 17
ALK-Abello A/S, Key Manufacturing Facilities 19
ALK-Abello A/S, Key Competitors 26
ALK-Abello A/S, Ratios based on current share price 27
ALK-Abello A/S, Annual Ratios 28
ALK-Abello A/S, Interim Ratios 31
ALK-Abello A/S, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 33
ALK-Abello A/S, Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015 34
ALK-Abello A/S, Recent Deals Summary 35
Currency Codes 41
Capital Market Ratios 41
Equity Ratios 42
Profitability Ratios 42
Cost Ratios 43
Liquidity Ratios 43
Leverage Ratios 44
Efficiency Ratios 44



List of Figures
ALK-Abello A/S, Pipeline Products by Therapy Area 10
ALK-Abello A/S, Pipeline Products by Development Phase 11
ALK-Abello A/S, Performance Chart (2010 – 2014) 30
ALK-Abello A/S, Ratio Charts 32
ALK-Abello A/S, Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 33
ALK-Abello A/S, Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015 34

Report Delivery

PDF SWOT Analysis Report An Electronic PDF copy of this Report will be sent to you via email.

Please allow up to 2 business days for the reports to arrive to your mailbox as some of our publishers prefer to send you the reports directly.

Purchase this Report today

Price: $125

Report Licences Explanation

* Single User: Electronic PDF copy delivered via email. Report can be used by individual purchaser only.

* Site License: Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.

* Enterprise Wide License: Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.

If you require a Site License or Enterprise Wide License please contact us to issue you an invoice.

Customers who Viewed this Report also Viewed

Risk warning: Your capital may be at risk. CFD trading is suitable for experienced traders and not beginners.